Noroviruses cause one in five cases of viral gastroenteritis worldwide, and of the 300 million cases of norovirus infection annually, 260,000 people die.
Researchers from the University of North Carolina at Chapel Hill found that a vaccine using virus-like particles can elicit antibody responses to a wide range of vaccine and non-vaccine virus-like particles.
This means that norovirus immunity from a virus-like particles vaccine could overcome the ability of noroviruses to evade immunity by antigenic drift.
“These data reveal new information about complex norovirus immune responses to both natural exposure and to vaccination, and support the potential feasibility of an efficacious multivalent norovirus VLP vaccine for future use in human populations,” the study authors wrote.
More articles on vaccines:
FDA advisory committee to meet on Ebola vaccines in May
16 scientific, health issues with the greatest political divide
Penalties or incentives for staff flu shot campaign: Which is more effective?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
